Sanofi Requests Withdrawal of Diabetes Drug from FDA’s Accelerated Review Program Amid Dispute

WASHINGTON, In a surprising turn of events, pharmaceutical giant Sanofi has formally requested that the Food and Drug Administration (FDA) withdraw its type 1 diabetes drug, teplizumab, from Commissioner Marty Makary’s new expedited review program. This move comes after significant internal disagreements within the agency over the approval process for the drug.

The FDA missed its target decision date of April 21, raising concerns about political interference and the integrity of the regulatory process. The dispute centers on a disagreement between acting Center for Drug Evaluation and Research (CDER) Director Tracy Beth Høeg and FDA staff over whether to approve teplizumab.

Behind the Dispute

Typically, decisions regarding drug approvals are made by career scientists within the FDA, who rely on rigorous scientific data and clinical trials. However, this case is unusual because it involves a political appointee like Høeg becoming directly involved in the review of a single drug. Sources familiar with the dispute, speaking anonymously due to fear of reprisal, revealed that Høeg disagreed with the staff's recommendation to approve teplizumab.

Makary, who recently defended his leadership on CNBC, stated that overruling scientific staff by political leaders can lead to "disaster." He emphasized his support for review teams and their expertise, but the current situation suggests a more complex dynamic at play. The involvement of Høeg in this decision highlights the potential for political influence in what should be a purely scientific process.

The expedited review program, introduced by Makary, aims to speed up the approval process for promising drugs. However, the controversy surrounding teplizumab raises questions about the program's effectiveness and whether it might compromise the thoroughness of drug evaluations. Sanofi’s decision to withdraw from the program could be seen as a vote of confidence in the traditional, more rigorous review process.

What Comes Next

The withdrawal of teplizumab from the expedited review program is likely to delay its potential approval and availability to patients. This could have significant implications for individuals with type 1 diabetes who might benefit from the drug. Teplizumab has shown promise in clinical trials, potentially delaying the onset of the disease in at-risk individuals.

For Sanofi, this move may also impact their business strategy and timelines. The company will now need to navigate the standard FDA review process, which can take longer but is often perceived as more transparent and reliable by both patients and healthcare providers.

The broader implications of this dispute extend beyond a single drug. It highlights the ongoing tension between accelerating drug approvals to bring life-saving treatments to market faster and maintaining high standards of safety and efficacy. The FDA will need to address these concerns to maintain public trust in its regulatory processes.

In the coming weeks, it will be crucial for the FDA to communicate transparently about the reasons for the delay and any changes in the review process. This transparency is essential to ensure that both industry stakeholders and the public have confidence in the agency’s ability to make science-driven decisions without undue political influence.